PAVmed Secures $30 Million in Series D Preferred Stock Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy PAVM?
Source: PRnewswire
- Successful Financing: PAVmed has raised $30 million through the issuance of Series D Preferred Stock, which includes warrants that could yield an additional $30 million, significantly enhancing the company's capital base to support future business expansion.
- Capital Structure Optimization: The proceeds from this financing will be used to redeem all outstanding Series C Preferred Stock, eliminating a significant legacy capital structure overhang, thereby unlocking asset potential for shareholders and improving financial health.
- Cash Flow Enhancement: Following the financing transaction, PAVmed expects to add approximately $7.7 million in net cash flow, further strengthening its balance sheet and enhancing its competitiveness in the medical technology sector.
- Strategic Development Outlook: The company plans to convene a special meeting of shareholders by April 2026 to seek approval for converting the preferred stock into common stock, which, if successful, will provide greater flexibility and funding support for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAVM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAVM
Wall Street analysts forecast PAVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAVM is 17.00 USD with a low forecast of 17.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.580
Low
17.00
Averages
17.00
High
17.00
Current: 10.580
Low
17.00
Averages
17.00
High
17.00
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PAVmed Secures $30 Million in Series D Preferred Stock Offering
- Successful Financing: PAVmed has raised $30 million through the issuance of Series D Preferred Stock, which includes warrants that could yield an additional $30 million, significantly enhancing the company's capital base to support future business expansion.
- Capital Structure Optimization: The proceeds from this financing will be used to redeem all outstanding Series C Preferred Stock, eliminating a significant legacy capital structure overhang, thereby unlocking asset potential for shareholders and improving financial health.
- Cash Flow Enhancement: Following the financing transaction, PAVmed expects to add approximately $7.7 million in net cash flow, further strengthening its balance sheet and enhancing its competitiveness in the medical technology sector.
- Strategic Development Outlook: The company plans to convene a special meeting of shareholders by April 2026 to seek approval for converting the preferred stock into common stock, which, if successful, will provide greater flexibility and funding support for future growth.
See More
PAVmed Subsidiary Secures VA Contract for EsoGuard Test, Expanding Access to Over 9 Million Veterans
- Contract Approval: Lucid Diagnostics has secured a contract with the Department of Veterans Affairs for its EsoGuard test, significantly enhancing access across the nationwide healthcare system serving over 9 million veterans, thereby strengthening the company's competitive position in the healthcare market.
- Standardized Procurement: The contract allows VA hospitals to procure EsoGuard through a unified framework, ensuring pre-negotiated pricing aligned with Medicare payment standards, which simplifies the procurement process and reduces operational costs.
- Clinical Evidence Support: Lucid stated that the award reflects the clinical evidence supporting the EsoGuard test, further solidifying its potential for integration into standard clinical practice and possibly facilitating collaborations with other integrated health systems.
- Market Performance Analysis: PAVmed shares are currently trading at $11.46, 40.4% above the 20-day simple moving average but 0.8% below the 100-day average, indicating strong short-term performance but potential long-term weakness in market signals.
See More
Lucid Diagnostics Secures VA Contract for EsoGuard, Boosting PAVmed Stock by 291%
- Contract Approval: Lucid Diagnostics has secured a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing for over nine million veterans, which is expected to significantly enhance the company's influence in the healthcare market.
- Pricing Advantage: The contract includes pre-negotiated pricing aligned with Medicare payment rates, allowing VA facilities to procure EsoGuard through a streamlined process, further strengthening the product's market competitiveness.
- Stock Performance: PAVmed's stock surged by 291.11% to $17.80 on Wednesday, reflecting strong short-term market performance and aligning with the positive trends in the Nasdaq and S&P 500 indices.
- Technical Indicators: PAVmed is currently trading 167.1% above its 20-day simple moving average, indicating strong short-term technical indicators; although the relative strength index (RSI) is in neutral territory, the MACD shows bullish momentum, suggesting optimistic market sentiment.
See More
PAVmed Subsidiary Wins VA Contract for Esophageal Precancer Testing, Shares Surge 250%
- Contract Approval: PAVmed's subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide the EsoGuard Esophageal DNA Test, granting access to over nine million enrolled veterans, significantly enhancing the company's influence in the medical testing market.
- Stock Surge: PAVM shares skyrocketed over 250% on Wednesday morning, becoming a trending stock on Stocktwits, reflecting strong market optimism regarding the contract and potentially attracting more investor interest.
- Market Reaction: Following the contract announcement, retail sentiment for PAVM flipped from 'bearish' to 'extremely bullish', with message volumes surging, indicating increased investor confidence in the company's growth potential.
- Clinical Evidence Support: The President of Lucid Diagnostics stated that the VA's selection of EsoGuard reflects the strength of its clinical evidence, further solidifying the company's market position in early cancer prevention diagnostics.
See More
Netflix, Inc. (NFLX) Reports Q4 Earnings Beat but Issues Lower Q1 Guidance, Shares Down 3%
- Netflix Earnings Highlight: Netflix reported Q4 earnings per share of $0.56, beating the consensus estimate of $0.55, with revenue of $12.05 billion exceeding expectations of $11.97 billion; however, shares fell 3%, reflecting market concerns over future guidance.
- Cautious Future Outlook: The company guided for Q1 earnings per share of $0.76 and revenue of approximately $12.16 billion, which is below analyst expectations, indicating a cautious sentiment that may impact investor confidence moving forward.
- Advertising Revenue Growth: Netflix anticipates continued growth in advertising revenue and plans to invest across content, advertising initiatives, and newer formats including live events, video podcasts, and games, aiming to enhance its competitive edge and attract more users.
- Market Reaction: Despite exceeding earnings expectations, Netflix's stock dropped 3% to $84.20, indicating investor concerns about the company's growth prospects, which could affect its position in the highly competitive streaming market.
See More
Lucid Diagnostics (LUCD) Secures VA Contract for EsoGuard Esophageal DNA Test at Medicare Pricing
- Contract Award: Lucid Diagnostics (LUCD) has secured a contract from the U.S. Department of Veterans Affairs, allowing it to offer the EsoGuard Esophageal DNA Test at Medicare pricing, which is expected to significantly enhance the company's competitiveness in the healthcare market.
- Market Expansion: This contract enables Lucid to supply EsoGuard through a single, national VA procurement framework, further solidifying its market position within the largest integrated healthcare system in the U.S., likely leading to increased sales and market share.
- Strategic Partnership: Lucid's COO Shaun O'Neil remarked that the partnership with the U.S. Department of Veterans Affairs will expand veterans' access to EsoGuard, demonstrating the company's commitment to improving veterans' health and enhancing its brand image.
- Stock Price Reaction: Following the contract announcement, Lucid's stock rose approximately 10% in premarket trading, reflecting the market's positive response to this significant contract, which may drive future investments and growth for the company.
See More
PAVmed Secures $30 Million in Series D Preferred Stock Offering
- Successful Financing: PAVmed has raised $30 million through the issuance of Series D Preferred Stock, which includes warrants that could yield an additional $30 million, significantly enhancing the company's capital base to support future business expansion.
- Capital Structure Optimization: The proceeds from this financing will be used to redeem all outstanding Series C Preferred Stock, eliminating a significant legacy capital structure overhang, thereby unlocking asset potential for shareholders and improving financial health.
- Cash Flow Enhancement: Following the financing transaction, PAVmed expects to add approximately $7.7 million in net cash flow, further strengthening its balance sheet and enhancing its competitiveness in the medical technology sector.
- Strategic Development Outlook: The company plans to convene a special meeting of shareholders by April 2026 to seek approval for converting the preferred stock into common stock, which, if successful, will provide greater flexibility and funding support for future growth.
See More
PAVmed Subsidiary Secures VA Contract for EsoGuard Test, Expanding Access to Over 9 Million Veterans
- Contract Approval: Lucid Diagnostics has secured a contract with the Department of Veterans Affairs for its EsoGuard test, significantly enhancing access across the nationwide healthcare system serving over 9 million veterans, thereby strengthening the company's competitive position in the healthcare market.
- Standardized Procurement: The contract allows VA hospitals to procure EsoGuard through a unified framework, ensuring pre-negotiated pricing aligned with Medicare payment standards, which simplifies the procurement process and reduces operational costs.
- Clinical Evidence Support: Lucid stated that the award reflects the clinical evidence supporting the EsoGuard test, further solidifying its potential for integration into standard clinical practice and possibly facilitating collaborations with other integrated health systems.
- Market Performance Analysis: PAVmed shares are currently trading at $11.46, 40.4% above the 20-day simple moving average but 0.8% below the 100-day average, indicating strong short-term performance but potential long-term weakness in market signals.
See More
Lucid Diagnostics Secures VA Contract for EsoGuard, Boosting PAVmed Stock by 291%
- Contract Approval: Lucid Diagnostics has secured a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing for over nine million veterans, which is expected to significantly enhance the company's influence in the healthcare market.
- Pricing Advantage: The contract includes pre-negotiated pricing aligned with Medicare payment rates, allowing VA facilities to procure EsoGuard through a streamlined process, further strengthening the product's market competitiveness.
- Stock Performance: PAVmed's stock surged by 291.11% to $17.80 on Wednesday, reflecting strong short-term market performance and aligning with the positive trends in the Nasdaq and S&P 500 indices.
- Technical Indicators: PAVmed is currently trading 167.1% above its 20-day simple moving average, indicating strong short-term technical indicators; although the relative strength index (RSI) is in neutral territory, the MACD shows bullish momentum, suggesting optimistic market sentiment.
See More
PAVmed Subsidiary Wins VA Contract for Esophageal Precancer Testing, Shares Surge 250%
- Contract Approval: PAVmed's subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide the EsoGuard Esophageal DNA Test, granting access to over nine million enrolled veterans, significantly enhancing the company's influence in the medical testing market.
- Stock Surge: PAVM shares skyrocketed over 250% on Wednesday morning, becoming a trending stock on Stocktwits, reflecting strong market optimism regarding the contract and potentially attracting more investor interest.
- Market Reaction: Following the contract announcement, retail sentiment for PAVM flipped from 'bearish' to 'extremely bullish', with message volumes surging, indicating increased investor confidence in the company's growth potential.
- Clinical Evidence Support: The President of Lucid Diagnostics stated that the VA's selection of EsoGuard reflects the strength of its clinical evidence, further solidifying the company's market position in early cancer prevention diagnostics.
See More
Netflix, Inc. (NFLX) Reports Q4 Earnings Beat but Issues Lower Q1 Guidance, Shares Down 3%
- Netflix Earnings Highlight: Netflix reported Q4 earnings per share of $0.56, beating the consensus estimate of $0.55, with revenue of $12.05 billion exceeding expectations of $11.97 billion; however, shares fell 3%, reflecting market concerns over future guidance.
- Cautious Future Outlook: The company guided for Q1 earnings per share of $0.76 and revenue of approximately $12.16 billion, which is below analyst expectations, indicating a cautious sentiment that may impact investor confidence moving forward.
- Advertising Revenue Growth: Netflix anticipates continued growth in advertising revenue and plans to invest across content, advertising initiatives, and newer formats including live events, video podcasts, and games, aiming to enhance its competitive edge and attract more users.
- Market Reaction: Despite exceeding earnings expectations, Netflix's stock dropped 3% to $84.20, indicating investor concerns about the company's growth prospects, which could affect its position in the highly competitive streaming market.
See More
Lucid Diagnostics (LUCD) Secures VA Contract for EsoGuard Esophageal DNA Test at Medicare Pricing
- Contract Award: Lucid Diagnostics (LUCD) has secured a contract from the U.S. Department of Veterans Affairs, allowing it to offer the EsoGuard Esophageal DNA Test at Medicare pricing, which is expected to significantly enhance the company's competitiveness in the healthcare market.
- Market Expansion: This contract enables Lucid to supply EsoGuard through a single, national VA procurement framework, further solidifying its market position within the largest integrated healthcare system in the U.S., likely leading to increased sales and market share.
- Strategic Partnership: Lucid's COO Shaun O'Neil remarked that the partnership with the U.S. Department of Veterans Affairs will expand veterans' access to EsoGuard, demonstrating the company's commitment to improving veterans' health and enhancing its brand image.
- Stock Price Reaction: Following the contract announcement, Lucid's stock rose approximately 10% in premarket trading, reflecting the market's positive response to this significant contract, which may drive future investments and growth for the company.
See More
